权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

A Comprehensive 5K Plus Glycan Microarray

综合 5K Plus 聚糖微阵列

基本信息

批准号：
10557232
负责人：
Lei Li
金额：
$ 45.4万
依托单位：
Z BIOTECH, LLC
依托单位国家：
美国
项目类别：
财政年份：
2017
资助国家：
美国
起止时间：
2017-08-01 至 2025-01-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10557232
关键词：
Address Affinity Avidity Binding Biological Biological Markers Biotechnology Body Fluids Businesses Cell surface Cells Characteristics Collection Complex Computer software Custom Data Analyses Data Scientist Data Set Databases Development Disease Engineering Enzymes Event Financial cost Fostering Funding Glycobiology Glycopeptides Grant Image Immune system Immunotherapy Industrialization Intuition Investments Lectin Libraries Mannose Marketing Mediating Methods Mind Mucins Natural Source Pharmacologic Substance Phase Physiological Polysaccharides Positioning Attribute Process Production Proteins Provider Public Health Quality Control Research Research Institute Research Personnel Resources Route Scientist Signal Transduction Small Business Innovation Research Grant Specific qualifier value Specificity Spottings Structure Sulfate Surface Systems Integration Therapeutic Time Universities Vaccines Vendor analysis pipeline automated analysis commercial application comparative cost experience insight macromolecule manufacturing cost manufacturing scale-up molecular recognition new technology programs receptor research and development scale up sugar nucleotide surface coating tool

项目摘要

Project Summary / Abstract The Glycan Array has proven a valuable tool in the study of glycans. Comparatively the Glycan Array gives the greatest view of glycan binding specificity for the lowest cost in terms of analytical turn-around time and financial cost. The Glycan Array is far from well optimized in our mind. There are three key limitations to an array-based approach with high throughput glycan-protein interaction profiling: 1) glycan arrays suffer from a systematic lack of sensitivity, 2) current array providers lack comprehensive glycan libraries with scalable synthetic routes, and 3) physiological glycan binding is intricate and complex and requires a lengthy analysis process. In Phase I we sought out to find solutions for each of these limitations. First, we developed a first of its kind Glycan Array that can analyze glycan binding avidity not just affinity. Second, we partnered with an elite group of chemists to produce a glycan library containing ~900 glycan structures, which is larger than that of the CFG and one of the largest ever. Third, we partnered with a group of data scientists and bioinformaticians to create a robust software package that automates the entire array data analysis process. Over the last three years we have formed valuable relationships with researchers and clinicians in research institutes, pharmaceutical companies and public health sectors. Z Biotech is perfectly positioned to facilitate the supply for increasing demand for biomedically relevant glycan arrays. In each of these endeavors Z Biotech sincerely thanks to the support of this SBIR grant. Now in Phase II we are seeking funds to continue to find solutions for these key limitations in Glycan Array. First, we will continue to invest heavily in R&D to ensure that our arrays offer superior insights compared to our competitors. We will also use funds from Phase II to scale up production to accommodate increasing demand. Second, we will team with Dr. Lei Li’s group at Georgia State University. Dr. Li is an outstanding glyco-scientist with experience in production of complex glycans, sugar nucleotides and glycan-related enzymes. With his effort we will maintain our current glycan library and add ~2,000 new glycan structures in Phase II. Third, we will complete Z Biotech’s custom software package. In Phase II we will bring this first of its kind glycan array data analysis package or solution to market.

项目摘要/摘要多聚糖阵列已被证明是研究多聚糖的一种有价值的工具。相比之下，多聚糖阵列提供了在分析周转时间和资金方面，以最低的成本获得最大的多糖结合专一性成本。在我们的脑海中，葡聚糖阵列远远没有得到很好的优化。基于阵列的存储有三个关键限制高通量糖蛋白相互作用图谱的方法：1)糖链阵列缺乏系统性 2)目前的阵列提供者缺乏具有可扩展合成路线的全面的糖链文库，以及 3)生理糖链结合是复杂复杂的，需要较长的分析过程。在第一阶段，我们试图为这些限制中的每一个找到解决方案。首先，我们开发了第一个此类多糖阵列可以分析多糖结合的亲和力，而不仅仅是亲和力。其次，我们与一群精英化学家合作，产生一个含有~900个糖链结构的糖链文库，它比CFG的糖链结构要大，并且是有史以来最大的一次。第三，我们与一组数据科学家和生物信息学家合作，创建了一个健壮的软件自动执行整个阵列数据分析过程的包。在过去的三年里，我们形成了与研究机构、制药公司和公共卫生部门。Z Biotech处于完美的地位，可以促进供应，以满足日益增长的需求与生物医学相关的糖链阵列。在这些努力中，Z Biotech由衷地感谢SBIR赠款的支持。现在处于第二阶段，我们正在寻求资金，继续为多糖阵列中的这些关键限制寻找解决方案。第一，我们将继续在研发方面投入巨资，以确保我们的阵列提供比竞争对手更出色的洞察力。我们还将使用第二阶段的资金扩大生产规模，以适应不断增长的需求。第二，我们将与雷丽博士在佐治亚州立大学的研究小组。李博士是一位杰出的糖科科学家，在生产复合葡聚糖、糖核苷酸和葡聚糖相关酶。在他的努力下，我们将保持我们目前的糖链文库并在第二阶段增加了~2,000个新的糖链结构。第三，我们将完成Z Biotech的自定义软件包。在第二阶段，我们将带来这类第一个糖链阵列数据分析包或面向市场的解决方案。